This is a phase I/II dose-escalation study of 225Ac-J591 administered together with
177Lu-PSMA-I&T (also known as PNT2002). The two study drugs are 225Ac-J591 and
177Lu-PSMA-I&T. Both drugs are designed to deliver radiation to prostate cancer cells; they
are known as radionuclide conjugates (radiation linked to antibodies/molecules that recognize
prostate cancer cells). The first phase of the study (phase I) will determine the highest
dose of the study drug that can be safely given. The second phase of the study (phase II)
will determine the effectiveness of the drug combination in patients with prostate cancer.